Kelsey Kern has been with CSL Behring since 2017 where she has managed global, end-to-end clinical trial supply in the Cardiovascular, Hereditary Angioedema (HAE), and Transplant therapeutic areas.
Kelsey Kern has been with CSL Behring since 2017 where she has managed global, end-to-end clinical trial supply in the Cardiovascular, Hereditary Angioedema (HAE), and Transplant therapeutic areas.